Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib

Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib

Abstract Lung cancer with complex epidermal growth factor receptor (EGFR) and CTNNB1 comutations is rare, and the efficacy of tyrosine kinase inhibitors (TKIs) is generally poor. Here, we encountered a lung cancer patient with complex EGFR (L858R and E709X) and CTNNB1 comutations who successfully re...

Full description

Bibliographic Details
Main Authors: Michihiro Kunishige, Seiya Ichihara, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Tsutomu Shinohara, Eiji Takeuchi
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Thoracic Cancer
Subjects:
afatinib
CTNNB1 mutation
E709X
L858R
non–small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14775

Internet

https://doi.org/10.1111/1759-7714.14775

Similar Items